share_log

JP Morgan Reinstates Overweight on BioCryst Pharma, Announces $10 Price Target

Benzinga ·  Nov 20, 2023 08:15

JP Morgan analyst Jessica Fye reinstates BioCryst Pharma (NASDAQ:BCRX) with a Overweight and announces $10 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment